|Source||Humanized (from mouse)|
|Target||Proprotein convertase subtilisin/kexin type 9 (PCSK9)|
|Chemical and physical data|
|Molar mass||145.1 kg/mol g·mol−1|
Bococizumab (USAN; development code RN316) is a drug that was in development by Pfizer targeting PCSK9 to reduce LDL cholesterol. Pfizer withdrew the drug from development in November 2016, determining that it was "not likely to provide value to patients, physicians or shareholders."
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Bococizumab" (PDF). American Medical Association.
- World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
- "Bococizumab (RN316) Significantly Reduced LDL Cholesterol In Statin-Treated Adults With High Cholesterol In A Phase 2b Study". Retrieved 29 December 2014.
- "Pfizer scraps cholesterol fighter, trims profit forecast". Reuters. Nov 1, 2016.
- Weinreich, M; Frishman, WH (2014). "Antihyperlipidemic therapies targeting PCSK9". Cardiology in review. 22 (3): 140–6. doi:10.1097/crd.0000000000000014. PMID 24407047.
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|
|This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.|